Earnings & Valuation
Here’s a comparison of Mangoceuticals and its competitors regarding revenue, net income, and valuation.
| Gross Revenue | Net Income | P/E Ratio | |
| Mangoceuticals | $866,792 | -$9.21 million | -5.65 |
| Competitors | $2.39 billion | $82.32 million | 15.75 |
Mangoceuticals lags behind competitors in revenue and earnings but is trading at a lower price-to-earnings ratio, making it more affordable.
Analyst Recommendations
Recent recommendations for Mangoceuticals and its competitors from MarketBeat.com:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mangoceuticals | 0 | 0 | 0 | 0 | N/A |
| Competitors | 36 | 288 | 416 | 147 | 2.76 |
Companies in the health sector have a potential upside of 15.41%. Analysts believe Mangoceuticals has less favorable growth prospects compared to its competitors.
Profitability
Here’s a comparison of net margins, return on equity, and return on assets:
| Net Margins | Return on Equity | Return on Assets | |
| Mangoceuticals | -1,053.93% | -243.34% | -200.73% |
| Competitors | -816.62% | -48.14% | -36.60% |
Ownership
56.7% of Mangoceuticals shares are held by institutional investors, slightly below the industry average of 61.8%. Company insiders hold 39.3% of shares, compared to 27.3% in the industry, indicating strong insider confidence.
Volatility & Risk
Mangoceuticals has a beta of 1.76, meaning its stock is 76% more volatile than the S&P 500. Competitors show even higher volatility with a beta of 3.97.
Summary
Mangoceuticals falls short in 9 out of 10 comparisons against its competitors.
Company Profile
Mangoceuticals, Inc. provides men’s wellness products via telemedicine, including erectile dysfunction and hair loss treatments. It was founded in 2021 in Dallas, Texas, and is a subsidiary of Cohen Enterprises, Inc.
Receive Daily News & Ratings for Mangoceuticals – Enter your email to get concise updates about Mangoceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
`
